Patents by Inventor Vladimir Coric

Vladimir Coric has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Rimegepant for CGRP related disorders
    Patent number: 11083724
    Abstract: Disclosed are methods of treating CGRP related disorders, e.g., migraine, by administering to a patient in need thereof rimegepant or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions comprising rimegepant and kits including the pharmaceutical compositions and instructions are also disclosed.
    Type: Grant
    Filed: May 27, 2020
    Date of Patent: August 10, 2021
    Assignee: Biohaven Pharmaceutical Ireland DAC
    Inventors: Vladimir Coric, Robert Croop
  • USE OF RILUZOLE PRODRUGS TO TREAT ALZHEIMER'S DISEASE
    Publication number: 20210212999
    Abstract: Disclosed are methods of treating Alzheimer's Disease by administering to a patient in need thereof a riluzole prodrug such as troriluzole. Pharmaceutical compositions and kits including the riluzole prodrugs are also disclosed.
    Type: Application
    Filed: January 18, 2021
    Publication date: July 15, 2021
    Inventors: Vladimir Coric, Robert Berman, Irfan Qureshi
  • CGRP ANTAGONISTS FOR TREATING MIGRAINE BREAKTHROUGH
    Publication number: 20210196699
    Abstract: Disclosed are methods of treating breakthrough migraine in patients using breakthrough CGRP antagonists. Also disclosed are methods for the prophylactic treatment of migraine.
    Type: Application
    Filed: February 17, 2021
    Publication date: July 1, 2021
    Inventors: Vladimir Coric, Robert Croop
  • USE OF ANTI-PD-1 ANTIBODY IN COMBINATION WITH ANTI-CD27 ANTIBODY IN CANCER TREATMENT
    Publication number: 20210139597
    Abstract: This invention provides methods for treating cancer in a subject comprising administering to the subject an anti-PD-1 antibody and an anti-CD27 antibody. In some embodiments, the cancer is colorectal cancer, rectal cancer, colon cancer, lung cancer, melanoma, ovarian cancer, head and neck cancer, or any combination thereof.
    Type: Application
    Filed: November 16, 2020
    Publication date: May 13, 2021
    Applicants: Bristol-Myers Squibb Company, Celldex Therapeutics, Inc.
    Inventors: Vladimir CORIC, Tibor KELER, Thomas DAVIS
  • GLUTAMATE AGENTS IN THE TREATMENT OF MENTAL DISORDERS
    Publication number: 20210093629
    Abstract: Methods of treating mental disorders, including anxiety disorders such as obsessive-compulsive disorder, are provided. The methods comprise administering an effective amount of a glutamate modulator to an individual in need thereof. Also provided are methods of enhancing the activity of a serotonin reuptake inhibitor (SRI) comprising co-administering a glutamate modulator and a serotonin reuptake inhibitor. Pharmaceutical composition comprising a serotonin reuptake inhibitor and a glutamate modulator are also provided.
    Type: Application
    Filed: December 7, 2020
    Publication date: April 1, 2021
    Inventors: Vladimir Coric, John H. Krystal, Gerad Sanacora
  • GLUTAMATE AGENTS IN THE TREATMENT OF MENTAL DISORDERS
    Publication number: 20210093630
    Abstract: Methods of treating mental disorders, including anxiety disorders such as obsessive-compulsive disorder, are provided. The methods comprise administering an effective amount of a glutamate modulator to an individual in need thereof. Also provided are methods of enhancing the activity of a serotonin reuptake inhibitor (SRI) comprising co-administering a glutamate modulator and a serotonin reuptake inhibitor. Pharmaceutical composition comprising a serotonin reuptake inhibitor and a glutamate modulator are also provided.
    Type: Application
    Filed: December 7, 2020
    Publication date: April 1, 2021
    Inventors: Vladimir Coric, John H. Krystal, Gerard Sanacora
  • SUBLINGUAL FORMULATION OF RILUZOLE
    Publication number: 20210038499
    Abstract: Disclosed is sublingual administration of riluzole. In particular, a method for treating a neuropsychiatric disorder or symptom by administering a sublingual formulation of riluzole is provided. In addition, a method of relieving or reducing oral pain using the sublingual formulation of riluzole is disclosed.
    Type: Application
    Filed: October 25, 2020
    Publication date: February 11, 2021
    Inventors: Vladimir Coric, Robert Berman, Ronald S. Vladyka, Amgad Saleh, Danny Yu
  • USE OF RILUZOLE PRODRUGS TO TREAT ATAXIAS
    Publication number: 20210023061
    Abstract: Disclosed are methods of treating ataxia by administering to a patient in need thereof a riluzole prodrug such as troriluzole. Pharmaceutical compositions and kits including the riluzole prodrugs are also disclosed.
    Type: Application
    Filed: November 11, 2018
    Publication date: January 28, 2021
    Inventors: Vladimir Coric, Robert Berman, Melissa Beiner, Gilbert L'Italien
  • RIMEGEPANT FOR CGRP RELATED DISORDERS
    Publication number: 20210000814
    Abstract: Disclosed are methods of treating CGRP related disorders, e.g., migraine, by administering to a patient in need thereof rimegepant or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions comprising rimegepant and kits including the pharmaceutical compositions and instructions are also disclosed.
    Type: Application
    Filed: March 25, 2019
    Publication date: January 7, 2021
    Inventors: Vladimir Coric, Robert Croop
  • USE OF IMMUNE CHECKPOINT INHIBITORS IN CENTRAL NERVOUS SYSTEMS NEOPLASMS
    Publication number: 20210000953
    Abstract: This disclosure provides a method for treating glioma in a subject comprising administering to the subject an anti-Programmed Death-1 (PD-1) antibody. In some embodiments, this invention relates to methods for treating glioma in a subject comprising administering to the subject a combination of an anti-cancer agent which is an anti-Programmed Death-1 (PD-1) antibody and another anti-cancer agent such as an anti-Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) antibody.
    Type: Application
    Filed: July 20, 2020
    Publication date: January 7, 2021
    Applicant: Bristol-Myers Squibb Company
    Inventors: Vladimir CORIC, Shinta CHENG
  • RIMEGEPANT FOR CGRP RELATED DISORDERS
    Publication number: 20200383969
    Abstract: Disclosed are methods of treating CGRP related disorders, e.g., migraine, by administering to a patient in need thereof rimegepant or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions comprising rimegepant and kits including the pharmaceutical compositions and instructions are also disclosed.
    Type: Application
    Filed: May 27, 2020
    Publication date: December 10, 2020
    Inventors: Vladimir Coric, Robert Croop
  • Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment
    Patent number: 10668152
    Abstract: This disclosure provides methods for treating cancer in a subject comprising administering to the subject an anti-PD-1 antibody and an anti-CD27 antibody. In some embodiments, the cancer is colorectal cancer, rectal cancer, colon cancer, lung cancer, melanoma, ovarian cancer, head and neck cancer, or any combination thereof.
    Type: Grant
    Filed: June 3, 2017
    Date of Patent: June 2, 2020
    Assignees: Bristol-Myers Squibb Company, Celldex Therapeutics, Inc.
    Inventors: Vladimir Coric, Tibor Keler, Thomas Davis
  • USE OF ANTI-PD-1 ANTIBODY IN COMBINATION WITH ANTI-CD27 ANTIBODY IN CANCER TREATMENT
    Publication number: 20200024355
    Abstract: This invention provides methods for treating cancer in a subject comprising administering to the subject an anti-PD-1 antibody and an anti-CD27 antibody. In some embodiments, the cancer is colorectal cancer, rectal cancer, colon cancer, lung cancer, melanoma, ovarian cancer, head and neck cancer, or any combination thereof.
    Type: Application
    Filed: July 8, 2019
    Publication date: January 23, 2020
    Applicants: Bristol-Myers Squibb Company, Celldex Therapeutics, Inc.
    Inventors: Vladimir CORIC, Tibor KELER, Thomas DAVIS
  • USE OF RILUZOLE, RILUZOLE PRODRUGS OR RILUZOLE ANALOGS WITH IMMUNOTHERAPIES TO TREAT CANCERS
    Publication number: 20190290619
    Abstract: Disclosed are methods of treating cancer using a combination of an immunotherapeutic agent, such as, for example, a PD-1, PD-L1 or CTLA-4 checkpoint inhibitor, and a glutamate modulating agent such as riluzole or trigriluzole. Pharmaceutical compositions including the immunotherapeutic agents and glutamate modulating agents are also disclosed.
    Type: Application
    Filed: May 19, 2017
    Publication date: September 26, 2019
    Inventor: Vladimir CORIC
  • Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment
    Patent number: 10392442
    Abstract: This invention provides methods for treating cancer in a subject comprising administering to the subject an anti-PD-1 antibody and an anti-CD27 antibody. In some embodiments, the cancer is colorectal cancer, rectal cancer, colon cancer, lung cancer, melanoma, ovarian cancer, head and neck cancer, or any combination thereof.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: August 27, 2019
    Assignees: Bristol-Myers Squibb Company, Celldex Therapeutics, Inc.
    Inventors: Vladimir Coric, Tibor Keler, Thomas Davis
  • USE OF GLUTAMATE MODULATING AGENTS WITH IMMUNOTHERAPIES TO TREAT CANCER
    Publication number: 20190175731
    Abstract: Disclosed are methods of treating cancer using a combination of an immunotherapeutic agent, such as, for example, a PD-1, PD-L1 or CTLA-4 checkpoint inhibitor, and a glutamate modulating agent such as riluzole or trigriluzole. Pharmaceutical compositions and kits including the immunotherapeutic agents and glutamate modulating agents are also disclosed.
    Type: Application
    Filed: May 19, 2017
    Publication date: June 13, 2019
    Inventor: Vladimir CORIC
  • GLUTAMATE AGENTS IN THE TREATMENT OF MENTAL DISORDERS
    Publication number: 20180318288
    Abstract: Methods of treating mental disorders, including anxiety disorders such as obsessive-compulsive disorder, are provided. The methods comprise administering an effective amount of a glutamate modulator to an individual in need thereof. Also provided are methods of enhancing the activity of a serotonin reuptake inhibitor (SRI) comprising co-administering a glutamate modulator and a serotonin reuptake inhibitor. Pharmaceutical composition comprising a serotonin reuptake inhibitor and a glutamate modulator are also provided.
    Type: Application
    Filed: July 10, 2018
    Publication date: November 8, 2018
    Inventors: Vladimir Coric, John H. Krystal, Gerard Sanacora
  • Glutamate agents in the treatment of mental disorders
    Patent number: 10052318
    Abstract: Methods of treating mental disorders, including anxiety disorders such as obsessive-compulsive disorder, are provided. The methods comprise administering an effective amount of a glutamate modulator to an individual in need thereof. Also provided are methods of enhancing the activity of a serotonin reuptake inhibitor (SRI) comprising co-administering a glutamate modulator and a serotonin reuptake inhibitor. Pharmaceutical composition comprising a serotonin reuptake inhibitor and a glutamate modulator are also provided.
    Type: Grant
    Filed: May 15, 2014
    Date of Patent: August 21, 2018
    Assignee: YALE UNIVERSITY
    Inventors: Vladimir Coric, John H. Krystal, Gerard Sanacora
  • SUBLINGUAL FORMATION OF RILUZOLE
    Publication number: 20180153794
    Abstract: Disclosed is sublingual administration of riluzole. In particular, a method for treating a neuropsychiatric disorder or symptom by administering a sublingual formulation of riluzole is provided. In addition, a method of relieving or reducing oral pain using the sublingual formulation of riluzole is disclosed.
    Type: Application
    Filed: November 17, 2015
    Publication date: June 7, 2018
    Inventors: Vladimir Coric, Robert Berman, Ronald S. Vladyka, Amgad Saleh, Danny Yu
  • SUBLINGUAL ADMINISTRATION OF RILUZOLE
    Publication number: 20180153862
    Abstract: Disclosed is sublingual administration of riluzole. In particular, a method for treating a neuropsychiatric disorder or symptom by administering a sublingual formulation of riluzole is provided. In addition, a method of relieving or reducing oral pain using the sublingual formulation of riluzole is disclosed.
    Type: Application
    Filed: November 17, 2015
    Publication date: June 7, 2018
    Inventors: Vladimir Coric, Robert Berman